The ClonePix® 2 Mammalian Colony Picker is a fully automated system for selecting high-value clones used in antibody discovery and cell line development. Screen more clones in less time with monoclonal verification on day zero, then screen and identify for highest producers in weeks, not months.
Hybridomas, CHO cells, stem cells and other cell types are imaged and selected based on user-defined parameters. Plate handling, barcode reading, and picking are fully integrated, and all data, including images, are saved for downstream analysis. The picker increases the probability of finding optimally produced cell lines and significantly reduces time and labor.
ClonePix 2 picker is 10x faster than labor-intensive limiting dilution and FACS. Our sophisticated software and integrated robotics enable a screening speed of > 10,000 clones per day.
Easily screen and select clones based on protein productivity, antigen-specificity, cell viability, and expression levels of tagged recombinant proteins.
Picking accuracy < 1 mm. Robotic picking reduces the risk of colony disturbance. Images of picked clones are stored with data.
White light identifies and measures clone morphology, size and proximity. Fluorescence indicates expression level and/or specificity. Up to five fluorescent filters are available for multiplexing.
A host of sterility features and options including a UV light process for sanitizing the interior of the instrument, as well as pin washing and halogen drying are standard.
Includes two storage stacks for source and destination plates, each with a capacity of 10 plates.
Semi-solid CloneMediaTM encourages single cells to grow into discreet colonies, and allows for ease of plating. The media allows for a higher density of clones to be screened.
Chemically defined and animal-free, CloneMedia cell-culture media, is optimized to increase productivity and aid in visualizing secreted antibodies when used with the CloneDetectTM detection agent.
The Advanced Workflow Engineering Solutions Team can customize the monoclonality system and offer added services such as integrated verification of monoclonality.
*Price, time to deliver, and specifications will vary based on mutually agreed technical requirements. Solution requirements may cause adjustment to standard performance.
Empower your team with data analysis that automatically generates a map of clones and their secretion levels from a series of images generated in situ. The ClonePix can also be customized to include image-based monoclonality assurance on day zero.* This means your team can screen in one round and then pick for the highest produces in weeks, not months.
All relevant data associated with each colony (including images taken before and after picking along with their picking coordinates) are automatically saved for review and downstream analysis.
The enhanced ClonePix 2 system can automatically screen and pick clones that are both high producing and monoclonal—all in one system. Screen more clones in less time with monoclonal verification on day zero, then screen and pick for highest produces in less than two weeks.
High-resolution imaging identifies desirable, clonal stem cell colonies for high-throughput colony screening and picking. Specialized picking pins allow the gentle transfer of adherent, feeder-free cells to high-density plates for clonal expansion and downstream analysis.
*Price, time to deliver, and specifications will vary based on mutually agreed technical requirements. Solution requirements may cause an adjustment to standard performance.
Custom solutions are subject to Molecular Devices Custom Products Purchase Terms.
How to screen and select clones of interest with high specificity and high efficiency is known as one of the bottlenecks for therapeutic antibody engineering and cell…
Protein G (Pro G) is a large cell surface binding protein that has a repeating 55-residue domain that binds with high affinity to the FC region of IgG. Together with…
Cell line development is a critical step in the process of generating biopharmaceutical molecules, such as monoclonal antibodies. The process often begins with transfecting the host cell type with the DNA encoding the therapeutic protein of interest allowing for random or directed integration of target DNA into the host cell genome. Thousands of clones are screened to isolate the rare high producing cells, a manual and time-consuming process.
Many proteins that express to the surface of cells are targets for the discovery and development of biopharmaceuticals. For instance, G-protein coupled receptors (GPCRs) are the largest class of cell-surface proteins and are targets for almost 40% of existing drugs. Discovery and selection of high value clones with elevated cell surface expression of GPCRs from a transfected pool of cells can be challenging. The ClonePix 2 System represents an automated method of screening large populations of cells that increases the probability of finding rare high-affinity binder or high producer.
An important component in identifying high-value clones is determining productivity of single cell-derived colonies. Screening for productivity using traditional approaches is laborious and time consuming, generally consisting of a multistep process that involves isolating single cells from limiting dilution followed by assessment of titer using ELISA. The ClonePix 2 system combines phenotype selection, single-cell isolation and productivity screening into a single step, resulting in dramatically shorter screening times and increased number of candidates.
The drug discovery landscape is shifting, with more scientists centering cell line development, disease models, and high-throughput screening methods around physiologically-relevant 3D cell models. The reason for this is clear: Using cellular model systems in research that closely mimic patient disease states or human organs can bring life-saving therapeutics to market – faster.
Antibody discovery typically refers to the screening and identification of monoclonal antibodies (mAbs) that target a specific epitope for the diagnosis and treatment of diseases. A common approach to generating monoclonal antibodies involves the fusion of a pre-mitotic cancer cell with a post-mitotic and terminal antibody-expressing B-cell from the spleen. The resulting fused cell is called a hybridoma and has the advantage of producing mAbs while dividing to regenerate itself. Screening hybridomas for binding specificity or productivity can be automated using the ClonePix 2 System.
Antibody discovery typically refers to the screening and identification of specific antibodies that target an antigen molecule for the diagnosis and treatment of diseases. The specificity of the antibody is based on its ability to bind the epitope, a unique region on the antigen molecule. Therapeutic antibodies are typically monoclonal, single cell-derived and target a unique epitope region on the antigen. The ClonePix 2 System automates screening and rapid detection of antigen-specific clones from a heterogenous population of cells.
Cell line development and assurance of monoclonality are critical steps in the process of generating biopharmaceutical molecules, such as monoclonal antibodies. A cell line can be established following the isolation of a single viable cell robustly expressing the protein of interest. A key milestone in this process is documenting evidence of clonality. Documentation of clonality is typically image-based, whereby an image of a single cell is produced and included in regulatory filings.
The Role of CRISPR in Scientific Breakthroughs in Microbiome Engineering Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) was first discovered in the genome of marine…
The product has been Irradiated and dosimetrically released in accordance with ISO 11137 – Sterilization of Health Care Products
How to screen and select clones of interest with high specificity and high efficiency is known as one of the bottlenecks for therapeutic antibody engineering and cell line development.…
Protein G (Pro G) is a large cell surface binding protein that has a repeating 55-residue domain that binds with high affinity to the FC region of IgG. Together with Protein A (Pro A…
In April 2021, we launched our Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process.…
Advancements in genetic engineering and synthetic biology have allowed numerous breakthroughs in recent decades. The importance of cell line development needs an honorable mention.…
Colony picking represents a powerful tool within the workflow of mammalian cell line development and the study of microbiology.
Discover why mAbs are key in the fight against SARS-CoV-2 and how the pandemic has shaped their discovery and development pipeline. Over the past three years, the development of…
Global research efforts are focused on understanding the SARS-CoV-2 virus in order to develop potential therapies for COVID-19. Join us as we explore a scientific timeline of key…
Obtain a comprehensive view of isolated single cells both in XY and Z dimensions on day 0 with the rapid Z-stack acquisition feature, which takes 2,400+ high-resolution, Z-plane images…
Advance your microbial and mammalian clone screening with proven, automated technologies
Since the first approval of recombinant insulin and human growth hormone in the early 1980s, a multitude of recombinant protein therapeutics have been approved by regulatory…
Regenerative medicine has the potential to provide cures for some of the world’s most devastating diseases. However, many roadblocks remain when it comes to moving these therapies fr…
Dwayne Carter gives us a taste of 3D bioprinting, clone screening, and Caribbean cuisine Dwayne Carter is a cell biologist and educator who joined Molecular Devices in November 2020…
For over 40 years, Molecular Devices has been at the forefront of technological advances which have contributed to significant scientific breakthroughs. To kick off the new year, we…
Immunology is now, more than anytime in recent history, one of the top fields of research. Monoclonal antibodies (mAbs) continue to enjoy intense interest as potential therapeutics.…
During the last decade, production of monoclonal antibodies (mAbs) and recombinant proteins using mammalian cells has led to a boom in the introduction of biotherapeutic proteins to…
CloneSelect Imager system produces objective, quantitative, and consistent results in less time to overcome the challenges associated with conventional cell confluence techniques.…
In this poster, we present data demonstrating that CloneMedia-PER.C6 supports the growth of cells into discrete colonies that can be imaged, ranked and picked using the ClonePix plat…
This PDF file explores ClonePix FL Technology which is based on the culture of mammalian cell lines in semisolid media originating from one single parent cell.
Production of best tolerated therapeutics is the core competence of Octagene. Haemophilia patients are treated lifelong with drugs to prevent bleeding. The daily risk of potential in…
Isolation of candidate mammalian cell clones by limited dilution, ring cloning or simply manual collection of colonies is a time consuming, resource intensive and costly procedure th…
Isolation of mammalian cell clones by limited dilution, ring cloning or simply manual collection of colonies is a time consuming, resource intensive and costly procedure that is pron…
Advances in cell culture techniques are facilitating development of novel screening assays which enable drug discovery programmes to rely on cell-based assays for high-throughput scr…
Screening cell populations for stable, high producing clones is a key rate-limiting step in the development and production of new protein therapeutics.
The Antibody Technology Shared Resource at the Fred Hutch Cancer Research Center offers custom antibody development to academic and industrial research groups. Their unique multiplex…
Animal cell culture technology has been thrust to the forefront of the biopharmaceutical industry because of the superior fidelity of mammalian cells in producing clinically relevant…
Molecular Devices offer products and unrivaled solutions that utilize imaging & intelligent image analysis to support basic research, pharmaceutical & biotherapeutic developm…
Check out the evolution timeline of CHO cells from CHO-ori to CHO-K1SV. Read about the properties of CHO cells that make them ideal for cell line development.
Explore a simple one-step hybridoma selective secretion assay for detecting and isolating antigen-specific, IgG-secreting hybridoma clones in as little as 8 days from fusion with min…
Download this PDF to learn about fast track cell Line development process with integrated automated colony picker.
Learn how you can screen for hihgly expressing GPCRs cells using ClonePix 2 system.
Download PDF to explore the process for developing serum-free CHO cell line.
The technology in ClonePix Systems removes the need for serial dilution or cell-sorting techniques. It allows monoclonal populations of high-secreting cells to be established in a much…
The ClonePix System was developed to overcome many of the drawbacks typically associated with isolating choice mammalian cell clones, during screening and selection of secretory cell…
The ability to select cells based on surface protein expression is of great use in establishing cell lines expressing the receptor(s) of interest for downstream phenotyping/genotyping…
Discovery and selection of high expressing GPCR clones from a transfected pool of cells can be challenging with regards to cell-line development. The technology in ClonePix 2 Systems…
The ClonePix System was employed in the high-throughput screening of hundreds of sub-cloned colonies from parental hybridoma material (historically parental line yields were less than…
Explore PDF to learn how you can accelerate your cell line development and get to your high value hits faster.
Stable Cell Line Development Workflow
Selection of high producing mammalian cells secreting non-mAb proteins workflow - SynBioBeta Lightning Talk
Optimized workflow for rapid identification of neutralizing antibodies against viral particles
Identification and Selection of GPCR Cell Lines with ClonePix 2
Latest Citations: For a complete list, please click here .
Since its inception in 1975, the hybridoma technology revolutionized science and medicine, facilitating discoveries in almost any field from the laboratory to the clinic. Many technological advancements have been developed since then, to create these “magical bullets.” Phage and yeast display libraries expressing the variable heavy and light domains of antibodies, single B-cell cloning from immunized animals of different species including humans or in silico approaches, all have rendered a myriad of newly developed antibodies or improved design of existing ones. However, still the majority of these antibodies or their recombinant versions are from hybridoma origin, a preferred methodology that trespass species barriers, due to the preservation of the natural functions of immune cells in producing the humoral response: antigen specific immunoglobulins. Remarkably, this methodology can be reproduced in small laboratories without the need of sophisticate equipment. In this chapter, we will describe the most recent methods utilized by our Monoclonal Antibodies Core Facility at the University of Texas–M.D. Anderson Cancer Center. During the last 10 years, the methods, techniques, and expertise implemented in our core had generated more than 350 antibodies for various applications.
Screening and characterization of cell lines for stable production are critical tasks in identifying suitable recombinant cell lines for the manufacture of protein therapeutics. To aid this essential function we have developed a methodology for the selection of antibody expressing cells using fluorescence based ClonePix FL colony isolation and flow cytometry analysis following intracellular staining for immunoglobulin G (IgG). Our data show that characterization of cells by flow cytometry early in the clone selection process enables the identification of cell lines with the potential for high productivity and helps to eliminate unstable cell lines. We further demonstrate a correlation between specific productivity (qP) and intracellular heavy chain (HC) content with final productivity. The unique combination of screening using ClonePix FL and the flow cytometry approaches facilitated more efficient isolation of clonal cell lines with high productivity within a 15 week timeline and which can be applied across NS0 and CHO host platforms. Furthermore, in this study we describe the critical parameters for the ClonePix FL colony based selection and the associated calculations to provide an assessment of the probability of monoclonality of the resulting cell lines.
The Holy Grail sought by all Bioprocess Cell Line Development (CLD) groups is achieving high yields from easily-cultured, robustly-growing cells in timelines measured in weeks rather than months. As the first bottleneck in process development, CLD must first birth its product for upstream and downstream groups to initiate their own reproductive cycles. To facilitate shortened CLD timelines, scientists have turned to new technologies and automation platforms. Emerging high-throughput instrumentation such as Clonepix and Automated MicroBioreactors (AMBR) have been enthusiastically integrated into stable cell line generation platforms; however, application of these methodologies among users is divergent.
Therapeutic recombinant monoclonal antibodies (mAbs) are commonly produced by high-expressing, clonal, mammalian cells. Creation of these clones for manufacturing remains heavily reliant on stringent selection and gene amplification, which in turn can lead to genetic instability, variable expression, product heterogeneity and prolonged development timelines. Inclusion of cis-acting ubiquitous chromatin opening elements (UCOE™) in mammalian expression vectors has been shown to improve productivity and facilitate high-level gene expression irrespective of the chromosomal integration site without lengthy gene amplification protocols. In this study we have used high-throughput robotic clone selection in combination with UCOE™ containing expression vectors to develop a rapid, streamlined approach for early-stage cell line development and isolation of high-expressing clones for mAb production using Chinese hamster ovary (CHO) cells. Our results demonstrate that it is possible to go from transfection to stable clones in only 4 weeks, while achieving specific productivities exceeding 20 pg/cell/day. Furthermore, we have used this approach to quickly screen several process-crucial parameters including IgG subtype, enhancer-promoter combination and UCOE™ length. The use of UCOE™-containing vectors in combination with automated robotic selection provides a rapid method for the selection of stable, high-expressing clones.